UChicago, Evelo Biosciences Sign Licensing Deal for Microbiome-Based Cancer Immunotherapy
Friday, April 22, 2016 - 03:20
in Mathematics & Economics
Evelo Biosciences and the University of Chicago have announced that they have entered into an exclusive worldwide license agreement to develop and commercialize a microbiome-based cancer immunotherapy.